What are the perceived advantages and disadvantages of non-nucleoside reverse transcriptase inhibitors as first-line therapy?
- 1 July 2000
- journal article
- review article
- Published by Wiley in HIV Medicine
- Vol. 1 (Supplement) , 11-14
- https://doi.org/10.1046/j.1468-1293.2000.00009.x
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- P43 Immune responses in patients changing from PI to NNRTI‐based HAARTHIV Medicine, 2000
- Evaluation of Lymph Node Virus Burden in Human Immunodeficiency Virus–Infected Patients Receiving Efavirenz‐Based Protease Inhibitor–Sparing Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2000
- Effect of ritonavir on lipids and post-heparin lipase activities in normal subjectsAIDS, 2000
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- Fat distribution and metabolic changes in patients with HIV infectionAIDS, 1999
- Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeterAIDS, 1999
- Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patientsAIDS, 1995
- Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complexThe Lancet, 1991